Sanuwave's UltraMIST product line joins Healogics iSupply, providing cost-effective wound care solutions to GPO members.
Quiver AI Summary
Sanuwave Health, Inc. has partnered with Healogics to incorporate its UltraMIST wound care product line into Healogics' iSupply Group Purchasing Organization. This collaboration allows iSupply members, including Wound Care Centers, home health agencies, and skilled nursing facilities, access to the UltraMIST system starting at select locations by the end of 2025. Sanuwave CEO Morgan Frank expressed enthusiasm about working with Healogics, a leader in wound care treatment and research, while Healogics Wound Care Supply President Richard Galentino highlighted the benefits of providing members with innovative, cost-effective solutions in wound healing technology. Sanuwave focuses on developing non-invasive medical systems for enhancing the body's healing processes across various health conditions.
Potential Positives
- Sanuwave's UltraMIST product line has been added to Healogics iSupply, expanding its market reach and availability to various healthcare providers.
- The collaboration with Healogics, a leader in wound care treatment and research, enhances Sanuwave's credibility and visibility in the healthcare community.
- This partnership is positioned to provide cost-saving solutions that are considered best-in-class for patient care, potentially improving patient outcomes and satisfaction.
Potential Negatives
- The press release includes a caution regarding forward-looking statements, highlighting potential risks and uncertainties that could impact future performance, which may create investor concern.
- While the addition of UltraMIST to Healogics iSupply marks a partnership opportunity, it may also indicate Sanuwave's reliance on external partnerships for market access, potentially reflecting limitations in their direct market penetration strategies.
FAQ
What is UltraMIST and how is it used?
UltraMIST is a next-generation wound care product aimed at enhancing healing through non-invasive technologies.
Who are the partners in the UltraMIST collaboration?
Sanuwave Health collaborates with Healogics Wound Care Supply to offer UltraMIST to GPO members.
When will UltraMIST be available to Healogics members?
The UltraMIST system is expected to be rolled out to iSupply members by the end of 2025.
What benefits does Healogics see in this partnership?
Healogics aims to provide its members with innovative, cost-saving wound healing solutions through the UltraMIST collaboration.
How does Sanuwave contribute to wound care?
Sanuwave focuses on developing non-invasive medical systems that enhance skin and tissue regeneration for effective wound treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNWV Insider Trading Activity
$SNWV insiders have traded $SNWV stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SNWV stock by insiders over the last 6 months:
- MANAGEMENT INC. OPALEYE purchased 1,267 shares for an estimated $38,360
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SNWV Revenue
$SNWV had revenues of $11.5M in Q3 2025. This is an increase of 22.34% from the same period in the prior year.
You can track SNWV financials on Quiver Quantitative's SNWV stock page.
$SNWV Hedge Fund Activity
We have seen 25 institutional investors add shares of $SNWV stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 106,625 shares (+28.8%) to their portfolio in Q3 2025, for an estimated $3,996,304
- SOLAS CAPITAL MANAGEMENT, LLC removed 95,387 shares (-32.2%) from their portfolio in Q3 2025, for an estimated $3,575,104
- CENTERBOOK PARTNERS LP added 73,959 shares (+528.7%) to their portfolio in Q3 2025, for an estimated $2,771,983
- STATE STREET CORP added 72,101 shares (+109.7%) to their portfolio in Q3 2025, for an estimated $2,702,345
- GOLDMAN SACHS GROUP INC added 69,790 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,615,729
- MILLENNIUM MANAGEMENT LLC removed 59,566 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,957,338
- BARCLAYS PLC removed 39,163 shares (-79.2%) from their portfolio in Q3 2025, for an estimated $1,467,829
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNWV Analyst Ratings
Wall Street analysts have issued reports on $SNWV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Northland Capital Markets issued a "Outperform" rating on 09/03/2025
- Roth Capital issued a "Buy" rating on 08/22/2025
To track analyst ratings and price targets for $SNWV, check out Quiver Quantitative's $SNWV forecast page.
$SNWV Price Targets
Multiple analysts have issued price targets for $SNWV recently. We have seen 2 analysts offer price targets for $SNWV in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Carl Byrnes from Northland Capital Markets set a target price of $55.0 on 09/03/2025
- Kyle Bauser from Roth Capital set a target price of $55.0 on 08/22/2025
Full Release
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization
Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members
EDEN PRAIRIE, Minn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of its UltraMIST product line to Healogics iSupply. With this expansion, UltraMIST becomes an option for iSupply members, including Wound Care Centers®, home health agencies, and skilled nursing facilities.
Sanuwave plans to roll out the UltraMIST system to Healogics iSupply members at initial locations by the end of 2025.
“We’re excited to collaborate with Healogics, the nation’s leader in wound care treatment and research,” said Morgan Frank, Sanuwave CEO . “Their network is one of the preeminent organizations in advanced wound care, and the opportunity to offer the UltraMIST product to its members and to collaborate with such a well-respected group is a fantastic opportunity for us, and we look forward to working with them.”
Richard Galentino, President of Healogics Wound Care Supply added, “We continue to look for opportunities to partner with innovative organizations focused on wound healing technologies. We are excited that Sanuwave will be joining our GPO and providing our members with a cost-saving solution that is best-in-class from a patient care perspective.”
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
About Healogics
For nearly 30 years, Healogics has led the nation in advanced wound care, transforming lives through evidence-based treatment and innovation. Guided by its mission to
FIND. TREAT. HEAL.™,
Healogics partners with hospitals and health systems across the country to deliver specialized care for patients with chronic wounds. Backed by the world’s largest wound care outcomes database and the Wound Science Initiative, Healogics continues to advance research and set new standards in healing. Learn more at
www.healogics.com
.
As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The Healogics Wound Science Initiative offers peer-reviewed research and advanced analytics in the pursuit of not only better outcomes, but a better way to provide care.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact: [email protected]
